# Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency

> **NCT02019667** · PHASE2 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 19 (actual)

## Conditions studied

- Metabolic Disease
- Seizures

## Interventions

- **DRUG:** SGS-742
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02019667
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-31
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-04-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02019667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02019667, "Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02019667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*